Pharmacophore modeling and parallel screening for PPAR ligands

We describe the generation and validation of pharmacophore models for PPARs, as well as a large scale validation of the parallel screening approach by screening PPAR ligands against a large database of structure-based models. A large test set of 357 PPAR ligands was screened against 48 PPAR models to determine the best models for agonists of PPAR-α, PPAR-δ, and PPAR-γ. Afterwards, a parallel screen was performed using the 357 PPAR ligands and 47 structure-based models for PPARs, which were integrated into a 1537 models comprising in-house pharmacophore database, to assess the enrichment of PPAR ligands within the PPAR hypotheses. For these purposes, we categorized the 1537 database models into 181 protein targets and developed a score that ranks the retrieved targets for each ligand. Thus, we tried to find out if the concept of parallel screening is able to predict the correct pharmacological target for a set of compounds. The PPAR target was ranked first more often than any other target. This confirms the ability of parallel screening to forecast the pharmacological active target for a set of compounds.

[1]  Jianhua Shen,et al.  Agonist–PPARγ interactions: Molecular modeling study with docking approach , 2003 .

[2]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[3]  J. Berger,et al.  (2R)-2-methylchromane-2-carboxylic acids: discovery of selective PPARalpha agonists as hypolipidemic agents. , 2005, Bioorganic & medicinal chemistry letters.

[4]  J. Fleckner,et al.  Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. , 2003, Journal of medicinal chemistry.

[5]  J. Berger,et al.  Design and synthesis of potent and subtype-selective PPARα agonists , 2006 .

[6]  N. Roglans,et al.  Uncoupling protein-3 mRNA levels are increased in white adipose tissue and skeletal muscle of bezafibrate-treated rats. , 1999, Biochemical and biophysical research communications.

[7]  Thierry Langer,et al.  Influenza Virus Neuraminidase Inhibitors: Generation and Comparison of Structure-Based and Common Feature Pharmacophore Hypotheses and Their Application in Virtual Screening , 2004, J. Chem. Inf. Model..

[8]  Theodora M. Steindl,et al.  Pharmacophore modeling, docking, and principal component analysis based clustering: combined computer-assisted approaches to identify new inhibitors of the human rhinovirus coat protein. , 2005, Journal of medicinal chemistry.

[9]  J. Lehmann,et al.  The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones , 1996 .

[10]  Thierry Langer,et al.  Pharmacophore Modeling and in Silico Screening for New P450 19 (Aromatase) Inhibitors , 2006, J. Chem. Inf. Model..

[11]  A. Dixit,et al.  Pharmacophore identification and 3D-QSAR studies in N-(2-benzoyl phenyl)-L-tyrosines as PPAR gamma agonists. , 2004, Bioorganic & medicinal chemistry.

[12]  J. Lehmann,et al.  Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. , 2000, Molecular cell.

[13]  Ingrid Pettersson,et al.  Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity , 2002 .

[14]  T. Willson,et al.  Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight. , 2001, Bioorganic & medicinal chemistry letters.

[15]  W. Hsueh,et al.  Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[16]  J. Lehmann,et al.  N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. , 1998, Journal of medicinal chemistry.

[17]  T. Burris,et al.  Benzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model. , 2004, Journal of medicinal chemistry.

[18]  L. Jendeberg,et al.  A New Class of Peroxisome Proliferator-activated Receptor Agonists with a Novel Binding Epitope Shows Antidiabetic Effects* , 2004, Journal of Biological Chemistry.

[19]  K. Umesono,et al.  Alteration of a Single Amino Acid in Peroxisome Proliferator-Activated Receptor-α (PPARα) Generates a PPARδ Phenotype , 2000 .

[20]  M. Yachi,et al.  Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship. , 2000, Bioorganic & medicinal chemistry letters.

[21]  David J. Diller,et al.  Use of Catalyst Pharmacophore Models for Screening of Large Combinatorial Libraries , 2002, J. Chem. Inf. Comput. Sci..

[22]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[23]  Thierry Langer,et al.  Parallel Screening: A Novel Concept in Pharmacophore Modeling and Virtual Screening , 2006, J. Chem. Inf. Model..

[24]  David Q. Liu,et al.  IN VITRO METABOLISM OF MK-0767 [(±)-5-[(2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL]-2-METHOXY-N-[[(4-TRIFLUOROMETHYL) PHENYL]METHYL]BENZAMIDE], A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR α/γ AGONIST. I. ROLE OF CYTOCHROME P450, METHYLTRANSFERASES, FLAVIN MONOOXYGENASES, AND ESTERASES , 2004, Drug Metabolism And Disposition.

[25]  Thierry Langer,et al.  Development and validation of an in silico P450 profiler based on pharmacophore models. , 2006, Current drug discovery technologies.

[26]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[27]  A. Tenenbaum,et al.  Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons , 2005, Cardiovascular Diabetology.

[28]  Leming Shi,et al.  Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators. , 2004, Bioorganic & medicinal chemistry letters.

[29]  S. Miyamoto,et al.  Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione. , 2001, Journal of molecular graphics & modelling.

[30]  Armin Ruf,et al.  A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Recruits PPARγ-Coactivator-1α, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro , 2006 .

[31]  J. Berger,et al.  Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity. , 2005, Journal of medicinal chemistry.

[32]  D. Diller,et al.  Kinases, homology models, and high throughput docking. , 2003, Journal of medicinal chemistry.

[33]  Ping-Chiang Lyu,et al.  Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies. , 2006, Journal of medicinal chemistry.

[34]  W. Miller,et al.  Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. , 2004, Journal of molecular endocrinology.

[35]  L. Moore,et al.  Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Lehmann,et al.  A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Terry K. Smith,et al.  Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids. , 2006, Journal of molecular biology.

[38]  R. Epple,et al.  1,3,5-Trisubstituted aryls as highly selective PPARδ agonists , 2006 .

[39]  P. Whittaker,et al.  PPAR‐α and ‐γ but not ‐δ agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF‐κB‐independent effect , 2003 .

[40]  Henrik Boström,et al.  Improving structure-based virtual screening by multivariate analysis of scoring data. , 2003, Journal of medicinal chemistry.